Anti-Anginal Effectiveness and Tolerability of Trimetazidine Modified Release 80 Mg Once Daily in Stable Angina Patients in Real-World Practice
|
01.09.2018 |
Glezer M.
Vygodin V.
Nekrasova E.
Khlopina I.
Nubret K.
Agafonova Y.
Ternavsky S.
Bardukova O.
Kutyakova N.
Berestennikova Y.
Ustyugova V.
Filatova T.
Khalturina I.
Ishchenko K.
Karutskaja O.
Panikar V.
Bolkhovitina O.
Bondarev E.
Eremin I.
Kadashova S.
Frolova O.
Petukhova I.
Suvorov A.
Zhuchkova Y.
Kuhl M.
Rodionova L.
Musurok T.
Ivkova I.
Ermakov A.
Stukalova E.
Chumakov V.
Rubezhanskaja E.
Kotlova A.
Pushkareva A.
Dmitrieva L.
Bel’kina E.
Solov’eva O.
Panyulaytenene S.
Sarkisyan O.
Konovalova G.
Kuznetsova S.
Nikolaeva S.
Trubitsyna I.
Alekseeva O.
Kozmina M.
Babautseva N.
Kochetkova I.
Anokhin A.
Vovk E.
Buyko A.
Malahatka E.
Iskra M.
Shilonosov S.
Moiseenko G.
Tomm Y.
Stopyatuk N.
Grigorieva E.
Zaitseva A.
Zaitseva N.
Sirotkina I.
Kiyanichenko R.
Grigoriev S.
Medvedeva N.
Svatkov M.
Golubeva L.
Kozhevnikova L.
Chernova A.
Dolbilkin A.
Palvinskaya A.
Baranova T.
Habeeva T.
Khodus D.
Ermolaeva G.
Arbatskaja I.
Idiatullina V.
Egorova M.
Galimova I.
Kuklina M.
Mamatadzhiev A.
Rahmatullina R.
Kim Z.
Stepanova V.
Gerr I.
Levchenko G.
Dubinkina S.
Zoob R.
Krokhmal O.
Lisina S.
Kudryavtseva N.
Sitnikov D.
Lunegov D.
Evdokimova N.
Ivanova I.
Manilova A.
Bessergeneva O.
Mokhova E.
Kulchytska O.
Shulikina O.
Ananenko V.
Ivanova O.
|
Advances in Therapy |
|
0 |
Ссылка
© 2018, The Author(s). Introduction: Trimetazidine (TMZ) was shown to reduce angina symptoms and increase the exercise capacity in stable angina (SA) patients. A new formulation allowing a once-daily (od) dosage could improve patients’ satisfaction and adherence. Methods: ODA was a 3-month, observational, multicenter, prospective Russian study in SA patients with persistent symptoms despite therapy. Angina attack frequency, short-acting nitrate (SAN) consumption, adherence to antianginal medications, and overall efficacy and tolerability of TMZ 80 mg od were assessed in a real-world setting. Results: A total of 3066 patients were included (mean age 62.8, 48% male). After 3 months, TMZ 80 mg od treatment led to a significant (p < 0.001) decrease in angina attack frequency (from 4.7 ± 3.5 to 0.9 ± 1.3/week) and SAN use (from 4.5 ± 3.9 to 0.7 ± 1.3/week). Overall tolerability and effectiveness were rated as “very good” by the majority of physicians. Medication adherence improved significantly, with good adherence reported by 56% of patients (vs. 24% at baseline, p < 0.0001) and non-adherence by 3% (vs. 36% at baseline, p < 0.0001) at month 3. Patient satisfaction with TMZ od was 9.5 [on a scale of 1 to 10 (very satisfied)]. Patients reported improved physical activity: more patients reported no limitations (15% vs. 1% at baseline p < 0.01), slight limitation (46% vs. 5% at baseline, p < 0.001) or moderate limitation (30% vs. 23%, p < 0.01) and fewer patients reported substantial limitation (8% vs. 52% at baseline, p < 0.001) or very marked reduction (1% vs. 19% at baseline, p < 0.01) at month 3. Conclusion: In this prospective, observational study, TMZ 80 mg od effectively reduced angina attacks and SAN consumption, improved physical activity and adherence and was well tolerated in chronic SA patients. Trial Registration: ISRCTN registry Identifier, ISRCTN97780949. Funding: Servier. Plain Language Summary: Plain language summary available for this article.
Читать
тезис
|
The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Durations: Results from the CHOICE-2 Study
|
01.07.2018 |
Glezer M.
Uskov V.
Goncharenko I.
Prasolova T.
Guseva V.
Shinkar A.
Samsonova S.
Vikhrova I.
Kuz’kina S.
Mitina L.
Timofeeva I.
Archakova T.
Kovaleva N.
Romanova E.
Tivon Y.
Antonova Y.
Kurganova O.
Davydova N.
Klyuchantseva O.
Popovskaya Y.
Kharitonova E.
Kuzmina T.
Buzmakova K.
Kaplenko L.
Pospelova N.
Stepanova A.
Kolbasheva N.
Krasnova G.
Pal’vinskaya A.
Toloknova V.
Bikmullina R.
Gainullina A.
Kedrina E.
Mikhailova S.
Nabiullina T.
Nizamova A.
Uskova A.
Yushkova A.
Andreeva O.
Fedotova G.
Bessergeneva O.
Gavrilyuk D.
Ehalo N.
Zlobina M.
Zhemartseva E.
Markushina I.
Pavlovets V.
Sobolenko A.
Apanovich I.
Kireeva N.
Maksimova I.
Butz T.
Pavlova I.
Bachurina S.
Orlyachenko S.
Zaitseva T.
Beznogova V.
Litsis N.
Novozhenina A.
Abramyan L.
Adamyan M.
Askerko S.
Bolmosov A.
Vasilieva I.
Volodova S.
Grishko P.
Zherebetskaya E.
Zemlyanaya N.
Klyshnikova L.
Kononchik E.
Kuznetsova N.
Kuz’minova I.
Marmurova I.
Mikhailova R.
Mordovina I.
Nazarkina O.
Perepechko A.
Pivovarova N.
Potapova T.
Prokofiev D.
Proniushkina N.
Savelieva E.
Semovskikh N.
Timonenkova L.
Fomin V.
Furman O.
Tsutsieva R.
Chibrikina M.
Shoshina I.
Yashchenko E.
Bocharova T.
Demyanenko O.
Zhukova L.
Melnikov A.
Merkulieva I.
Tyasina E.
Pakholkova N.
Rogozina S.
Chugunova I.
Brazhnik M.
|
Advances in Therapy |
|
0 |
Ссылка
© 2018, The Author(s). Introduction: Trimetazidine (TMZ) has been shown to reduce angina symptoms and to increase exercise capacity in randomized clinical trials, but more extensive data would be useful to assess its effects in real-world clinical practice and in patients with different durations of disease. Methods: CHOICE-2 was a Russian, multicenter, 6-month, open-label, prospective observational study that assessed the effect of adding TMZ modified release 35 mg bid to antianginal treatment in a real-world setting. The present analysis of CHOICE-2 results explored the effects of adding TMZ to background antianginal therapies with regard to the duration of stable angina. Results: A total of 741 patients with known durations of disease were divided into four groups according to stable angina pectoris (AP) duration, ranging from less than 1 year to more than 9 years. Addition of TMZ led to a significant decrease in the frequency of angina attacks and in the use of short-acting nitrates in all groups. In patients with recently diagnosed angina (AP duration < 1 year), the average number of angina attacks per week decreased significantly from 3.75 ± 4.63 to 0.67 ± 1.51 and in those with advanced disease (AP duration > 9 years) from 5.63 ± 5.24 to 1.32 ± 2.07. Angina-free walking distance also improved significantly. Addition of TMZ also improved patient well-being. Results were achieved rapidly (within 2 weeks), were maintained over 6 months, and were obtained in all patient groups regardless of angina duration. Conclusion: TMZ added to other antianginal therapies proved to be effective for reducing angina attacks and short-acting nitrate use, increasing angina-free walking distance, and improving patient well-being in a real-life setting, irrespective of angina duration, including patients with recently diagnosed angina. This provides an opportunity for intensification of treatment early on in the disease process, with the aim of decreasing angina burden and improving patient quality of life. Funding: Servier. Trial Registration: ISRCTN identifier ISRCTN65209863. Plain Language Summary: Plain language summary available for this article.
Читать
тезис
|
Efficacy of Ivabradine in Combination with Beta-Blockers Versus Uptitration of Beta-Blockers in Patients with Stable Angina (CONTROL-2 Study)
|
01.03.2018 |
Glezer M.
Vasyuk Y.
Karpov Y.
|
Advances in Therapy |
|
1 |
Ссылка
© 2018, The Author(s). Introduction: Heart rate (HR) reduction is an integral part of antianginal therapy, but many patients do not reach the guideline-recommended target of less than 60 bpm despite high use of beta-blockers (BB). Failure to uptitrate BB doses may be partly to blame. To explore other options for lowering HR and improving angina control, CONTROL-2 was initiated to compare the efficacy and tolerability of the combination of BBs with ivabradine versus uptitration of BBs to maximal tolerated dose, in patients with stable angina. Methods: This multicenter, open, randomized study included 1104 patients with Canadian Cardiovascular Society (CCS) class II or III stable angina, in sinus rhythm, and on background stable treatment with non-maximal recommended doses of BBs. Consecutive patients were allocated to ivabradine + BB or BB uptitration in a 4:1 ratio. Results: At the end of the study (week 16), addition of ivabradine to BB treatment and BB uptitration resulted in reduction in HR (61 ± 6 vs. 63 ± 8 bpm; p = 0.001). At week 16, significantly more patients on ivabradine + BB were in CCS class I than with BB uptitration (37.1% vs. 28%; p = 0.017) and significantly more patients were angina-free (50.6% vs. 34.2%; p < 0.001). Patient health status based on the visual analogue scale (VAS) was also better in the ivabradine + BB group. Adverse events (AEs) were significantly more common with BB uptitration than with the ivabradine + BB combination (18.4% vs. 9.4%, p < 0.001). Conclusion: In patients with stable angina, combination therapy with ivabradine + BB demonstrated good tolerability, safety, and more pronounced clinical improvement, compared to BB uptitration. Trial Registration: ISRCTN30654443. Funding: Servier.
Читать
тезис
|
Possibilities of antianginal therapy in improvement of quality of life of patients with stable angina of effort
|
01.01.2018 |
Zakharova V.
Kozlova N.
Sizova Z.
Beloborodova A.
|
Electronic Journal of General Medicine |
|
0 |
Ссылка
© 2018 by the authors; licensee Modestum Ltd., UK. Objective: High prevalence of ischemic heart disease (IHD) is currently both of medical and social concern, thus requiring treatment with drugs capable of influencing not only the prognosis of the disease but also quality of life of patients. This study was undertaken to investigate the possibilities of antianginal therapy with nicorandil and isosorbide dinitrate in order to improve quality of life of patients with stable angina pectoris. Method: The authors carried out a comprehensive examination of a total of eighty-four 44-to-76-year-old patients suffering from IHD with functional class 2-3 stable angina of effort and followed up in ambulatory settings. The patients were randomized into two groups of treatment to receive either nicorandil or isosorbide dinitrate as antianginal agents added to basic therapy. The groups of patients did not significantly differ by anamnestic and demographic characteristics. The duration of follow up amounted to 24 months. We determined the physical and mental components of health-related quality of life and their dynamics on the background of antianginal therapy with nicorandil and isosorbide dinitrate. The parameters of quality of life were evaluated by the findings of two screening tools: the General Health Questionnaire (GHQ-28) and Seattle Angina Questionnaire (SAQ). Results: The findings obtained within the timeframe of the study demonstrated that patients suffering from FC 2-3 stable angina of effort and taking standard therapy with beta-adrenoblokers, calcium antagonists, and antiplatelet drugs were found to have a decrease in their quality of life. The lowest scores were observed by the scales reflecting the psychological component of health, whereas the scores of physical limitation, angina stability, and angina frequency were considerably better. After 24 weeks of treatment with nicorandil and isosorbide dinitrate, the patients of both groups were found to have significantly improved scores for quality of life assessed by the SAQ on all scales. Initially high scores by the GHQ characterizing the patient’s psychological discomfort were revealed in both groups of patients, with no statistically significant differences between the groups. The highest score was revealed by the scales of somatic symptoms and social dysfunction in both the nicorandil group (11.8 and 13.2 points, respectively) and isosorbide dinitrate group (12.1 and 13.5 points, respectively). The mentioned alterations underline the significance of such disease as IHD in adaptation of the patient to the social environment. Angina attacks, physical limitations lead to deterioration of the emotional state and interfere with daily activity. High scores by the scales of anxiety and depression suggested a low level of mental health of IHD patients with stable angina pectoris. After 24 months of treatment, manifestations of anxiety and depression in patients of both groups significantly decreased (with the results comparable in both groups), with clear advantage in the nicorandil group. Conclusion: Nicorandil turned out to be superior to isosorbide dinitrate in improvement of physical and psychological components of quality of life of patients with stable angina of effort.
Читать
тезис
|
Taurin influence on clinical course of stable angina in postinfarction cardiosclerosis patients
|
01.01.2018 |
Vasilieva I.
Rezvan V.
|
Russian Journal of Cardiology |
|
0 |
Ссылка
© 2018, Silicea-Poligraf. All rights reserved. Aim. Study of efficacy and safety of taurin in management of stable angina patients with postinfarction cardiosclerosis. Material and methods. Totally, 95 postinfarction cardiosclerosis patients included, with stable angina of II and III functional class. The patients that were included, had refused revascularization. To the main group, 48 were included with added taurin (Dibicor, “PIK-Pharma”, Russia, 750 mg daily), and to comparison group — 47 patients that were taking standard treatment and placebo. Treatment duration 3 months. Results. Clinical efficacy of taurin in postinfarction cardiosclerosis and stable angina is confirmed by significant improvement of the following parameters: subjective state (decreased fatigue, less complaints on palpitation, less severity of dyspnea and rarer angina attacks), of the life quality parameters by Seattle questionnaire; echocardiographic parameters, normalized cardiac rhythm. Postive changes achieved on the basis therapy with taurin, remained for 3 months after drug discontinuation. Conclusion. Positive influence of taurin on clinical and instrumental parameters of patients make it to recommend its prescription for stable angina treatment in postinfarction cardiosclerosis patients.
Читать
тезис
|
What are the opportunities of prasugrel in the treatment of patients with acute coronary syndrome?
|
01.01.2018 |
Gilyarov M.
Konstantinova E.
|
Rational Pharmacotherapy in Cardiology |
|
0 |
Ссылка
© 2018, Stolichnaya Izdatelskaya Kompaniya. The aim of the review is presenting the possibilities and perspectives of the third generation of thienopyridine P2Y12 receptor inhibitor prasugrel in the treatment of patients with acute coronary syndrome (ACS). The main pathogenetic stage of ACS is intracoronary thrombosis, which develops on the surface of a damaged atherosclerotic plaque. The use of acetylsalicylic acid with addition of the second antiplatelet agent, so-called dual antiplatelet therapy, is a standard component in the treatment of any type of ACS, regardless of reperfusion and the selected treatment strategy. Due to some limitations in the use of clopidogrel as the second component of dual antiplatelet therapy, the possibility of prasugrel or ticagrelor usage should be considered in patients with ACS with percutaneous coronary intervention (PCI). Prasugrel therapy is associated with better clinical outcomes as compared with clopidogrel therapy in moderate or high-risk patients who undergo PCI. Because of higher bleeding risk and the lack of clinical benefits in special subgroups of patients, prasugrel must not be used in patients with a stroke or transient ischemic attack in the past. If, after a thorough individual benefit-risk assessment a decision is in favor of prescribing prasugrel to the patient older than 75 years or with a small body weight the maintenance dose of prasugrel is to be reduced by half. Real clinical practice data has shown that with following these recommendations prasugrel demonstrates optimal efficacy, safety, and even more significant impact on the prognosis than this in clinical trials. Prasugrel is able to reduce significantly the incidence of cardiovascular events such as cardiovascular death, myocardial infarction and stroke in patients with ACS who undergo PCI.
Читать
тезис
|